Table 6.

Schematic overview of studies involving lamotrigine in human experimental pain models

	Reference	Dose	Model	Main findings
Acute models	[77] (n= 18)	400 mg p.o.	Heat skin stimulation (1 min 45 °C) VAS	No parameters were affected
	[76] (n= 12)	300 mg p.o.	Stimulation of nasal mucosa by CO2 VAS, evoked brain potentials	VAS ↔ Evoked potentials: latency of the P100↑, amplitudes ↔
	[78] (n= 14)	300 mg p.o.	Heat and cold skin stimulation 1–1.5 °C s−1) warm and cool sensation, PDT Mechanical skin stimulation threshold to touch	No parameters were affected
	[81] (n= 12)	300 mg p.o.	Cold pressor test maximum pain (VAS)	Maximum pain ↓
Models inducing hyperalgesia	[77] (n= 18)	400 mg p.o.	Heat-capsaicin sensitization area of secondary HA to pinprick and allodynia to brushing	No parameters were affected
	[78] (n= 14)	300 mg p.o.	Intradermal capsaicin: area of secondary HA to pinprick, stroking and heat	No parameters were affected

In the column ‘Model’ the method for pain assessment is normal font, and the method for pain induction is bold. PDT, pain detection threshold; PTT, pain tolerance threshold; AUC, area under curve; VAS, visual analogue scale; HA, hyperalgesia.